PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Survival Rates for Prostate Cancer. [cited 19 Sep 2021]. Available from: https://www.cancer.org/cancer/prostate-cancer/detection-diagnosisstaging/survival-rates.html
   Google Scholar
• Haffner MC, Zwart W, Roudier MP, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18(2):79–92. doi: 10.1038/s41585-020-00400-w
   PubMed Web of Science ®Google Scholar
• Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–262. doi: 10.1016/j.eururo.2020.09.042
   PubMed Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–1192. doi: 10.1111/j.1742-1241.2011.02799.x.
   PubMed Web of Science ®Google Scholar
• Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263–282. doi: 10.1016/j.eururo.2020.09.046
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Stadler WM, et al. Prostate cancer clinical trials Working group 3. Trial design and Objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials Working group 3. J Clin Oncol. 2016;34(12):1402–1418. doi: 10.1200/JCO.2015.64.2702
   PubMed Web of Science ®Google Scholar
• Satoh T, Ledesma D, Yoshihara N. The economic burden of metastatic castration resistant prostate cancer and skeletal related events in Japanese university hospitals. Asian Pac J Cancer Prev. 2018;19:21–26.
   PubMedGoogle Scholar
• Grochtdreis T, König HH, Dobruschkin A, et al. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: asystematic review. PLoS One. 2018;13(12):e0208063. doi: 10.1371/journal.pone.0208063
   PubMed Web of Science ®Google Scholar
• Sumanasuriya S, De Bono J. Treatment of advanced prostate cancer—A review of current therapies and future promise. Cold Spring Harb Perspect Med. 2018;8(6):a030635. doi: 10.1101/cshperspect.a030635
   PubMed Web of Science ®Google Scholar
• Sathianathen NJ, Philippou YA, Kuntz GM, et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2018;10(10):012816. doi: 10.1002/14651858.CD012816.pub2
   Google Scholar
• Heck MM, Tauber R, Schwaiger S, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75(6):920–926. doi: 10.1016/j.eururo.2018.11.016
   PubMed Web of Science ®Google Scholar
• Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90. doi: 10.2967/jnumed.116.183194
   PubMed Web of Science ®Google Scholar
• Barber TW, Singh A, Kulkarni HR, et al. Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019;60(7):955–962. doi: 10.2967/jnumed.118.216820
   PubMed Web of Science ®Google Scholar
• Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol. 2005;288(5):975–981. doi: 10.1152/ajpcell.00506.2004
   PubMed Web of Science ®Google Scholar
• Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58(18):4055–4060.
   PubMed Web of Science ®Google Scholar
• Gallicchio R, Giacomobono S, Nardelli A, et al. Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain. J Bone Miner Metab. 2014;32(4):434–440. doi: 10.1007/s00774-013-0507-0
   PubMed Web of Science ®Google Scholar
• Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23(21):4591–4601. doi: 10.1200/JCO.2005.05.160
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of Lutetium-177–Labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–5189. doi: 10.1158/1078-0432.CCR-13-0231
   PubMed Web of Science ®Google Scholar
• Okamoto S, Thieme A, Allmann J, et al. Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med. 2017;58(3):445–450. doi: 10.2967/jnumed.116.178483
   PubMed Web of Science ®Google Scholar
• Zhang H, Koumna S, Pouliot F, et al. PSMA theranostics: current landscape and future outlook. Cancers (Basel). 2021;13(16):4023. doi: 10.3390/cancers13164023
   PubMed Web of Science ®Google Scholar
• Ruigrok EAM, van Weerden WM, Nonnekens J, et al. The future of PSMA-Targeted radionuclide therapy: an overview of recent preclinical research. Pharmaceutics. 2019;11(11):560. doi: 10.3390/pharmaceutics11110560
   PubMed Web of Science ®Google Scholar
• Ruigrok EAM, van Vliet N, Dalm SU, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48(5):1339–1350. doi: 10.1007/s00259-020-05057-6
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Eppard E, Kürpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477–12488. doi: 10.18632/oncotarget.7245
   PubMedGoogle Scholar
• Baum RP, Kulkarni HR, Schuchardt C, et al. 177 Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57(7):1006–1013. doi: 10.2967/jnumed.115.168443
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Rahbar K, Kürpig S, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5(1):114. doi: 10.1186/s13550-015-0114-2
   PubMedGoogle Scholar
• Heck MM, Retz M, Alessandria DC, et al. Systemic radioligand therapy with 177 Lu labeled prostate specific membrane antigen Ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol. 2016;196(2):382–391. doi: 10.1016/j.juro.2016.02.2969
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-Targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177 Lu-labeled PSMA-617. J NuclMed. 2016;57(8):1170–1176. doi: 10.2967/jnumed.115.171397
   Google Scholar
• Rahbar K, Bode A, Weckesser M, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41(7):522–528. doi: 10.1097/RLU.0000000000001240
   PubMed Web of Science ®Google Scholar
• Kulkarni HR, Singh A, Schuchardt C, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013. J Nucl Med. 2016;57(Supplement 3):97S–104S. doi: 10.2967/jnumed.115.170167
   PubMedGoogle Scholar
• Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536–2544. doi: 10.1007/s00259-019-04485-3
   PubMed Web of Science ®Google Scholar
• Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–833. doi: 10.1016/S1470-2045(18)30198-0
   PubMed Web of Science ®Google Scholar
• Hofman MS, Emmett L, Sandhu S, et al. , TheraP trial Investigators and the Australian and New Zealand Urogenital and prostate cancer trials group. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804.
   PubMed Web of Science ®Google Scholar
• Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–1103. doi: 10.1056/NEJMoa2107322
   PubMed Web of Science ®Google Scholar
• Weineisen M, Schottelius M, Simecek J, et al. 68 Ga- and 177 Lu-labeled PSMA I&T: optimization of a PSMA-Targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56(8):1169–1176. doi: 10.2967/jnumed.115.158550
   PubMed Web of Science ®Google Scholar
• Emmett L, Willowson K, Violet J, et al. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64(1):52–60. doi: 10.1002/jmrs.227
   PubMed Web of Science ®Google Scholar
• Kurth J, Krause BJ, Schwarzenböck SM, et al. External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. EJNMMI Res. 2018;8(1):32. doi: 10.1186/s13550-018-0386-4
   PubMedGoogle Scholar
• Demir M, Abuqbeitah M, Uslu-Beşli L, et al. Evaluation of radiation safety in 177 Lu-PSMA therapy and development of outpatient treatment protocol. J Radiol Prot. 2016;36(2):269–278. doi: 10.1088/0952-4746/36/2/269
   PubMed Web of Science ®Google Scholar
• Kendi AT, Halfdanarson TR, Packard A, et al. Therapy with 177Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors. AJR Am J Roentgenol. 2019;213(2):309–317. doi: 10.2214/AJR.19.21123
   PubMed Web of Science ®Google Scholar
• Sjögreen Gleisner K, Chouin N, Gabina PM, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. EurJNucl Med Mol Imaging. 2022;49(6):1778–1809. doi: 10.1007/s00259-022-05727-7
   PubMed Web of Science ®Google Scholar
• Fanti S, Goffin K, Hadaschik BA, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):469–476. doi: 10.1007/s00259-020-04934-4
   PubMed Web of Science ®Google Scholar
• Seifert R, Kessel K, Schlack K, et al. Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis. Eur J Nucl Med Mol Imaging. 2020;47(9):2106–2112. doi: 10.1007/s00259-020-04703-3
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Rahbar K, Baum RP, et al. Prior therapies as prognostic factors of overall survival in metastatic castrationresistant prostate cancer patients treated with ([177]Lu)Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48(1):113–122. doi: 10.1007/s00259-020-04797-9
   PubMed Web of Science ®Google Scholar
• Suman S, Parghane RV, Joshi A, et al. Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort. Br J Radiol. 2019;92(1104):20190380. doi: 10.1259/bjr.20190380
   PubMed Web of Science ®Google Scholar
• Yordanova A, Linden P, Hauser S, et al. Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1073–1080. doi: 10.1007/s00259-018-4222-x
   PubMed Web of Science ®Google Scholar
• Yadav MP, Ballal S, Sahoo RK, et al. Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2019;213(2):275–285. doi: 10.2214/AJR.18.20845
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Bauman G, von Eyben R, et al. Optimizing PSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer. A systematic review and meta-analysis. Int J Mol Sci. 2020;21(23):9054. doi: 10.3390/ijms21239054
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Roviello G, Kiljunen T, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. EurJNucl Med Mol Imaging. 2018;45(3):496–508. doi: 10.1007/s00259-017-3895-x
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Singh A, Zhang J, et al. 177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. Oncotarget. 2019;10(25):2451–2461. doi: 10.18632/oncotarget.26789
   PubMedGoogle Scholar
• Kessel K, Seifert R, Schäfers M, et al. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617. Theranostics. 2019;9(17):4841–4848. doi: 10.7150/thno.35759
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Kulkarni HR, Baum RP. Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy. Theranostics. 2020;10(11):4900–4902. doi: 10.7150/thno.44568
   PubMed Web of Science ®Google Scholar
• Yaxley WJ, McBean R, Wong D, et al. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer? Investig Clin Urol. 2021;62(6):650–657. doi: 10.4111/icu.20210097
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Kairemo K, Paller C, et al. 177Lu-PSMA radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials. Biomedicines. 2021;9(8):1042. doi: 10.3390/biomedicines9081042
   PubMed Web of Science ®Google Scholar
• Sadaghiani MS, Sheikhbahaei S, Werner RA, et al. 177 Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: an updated systematic review and meta-analysis. Prostate. 2022;82(7):826–835. doi: 10.1002/pros.24325
   PubMed Web of Science ®Google Scholar
• Yadav MP, Ballal S, Bal C, et al. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med. 2020;45(1):19–31. doi: 10.1097/RLU.0000000000002833
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59(5):795–802. doi: 10.2967/jnumed.117.203539
   PubMed Web of Science ®Google Scholar
• Sathekge M, Bruchertseifer F, Vorster M, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61(1):62–69. doi: 10.2967/jnumed.119.229229
   PubMed Web of Science ®Google Scholar
• Feuerecker B, Tauber R, Knorr K, et al. Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of Lutetium-177-PSMA. Eur Urol. 2021;79(3):343–350. doi: 10.1016/j.eururo.2020.11.013
   PubMed Web of Science ®Google Scholar
• Yadav MP, Ballal S, Sahoo RK, et al. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2020;10(20):9364–9377. doi: 10.7150/thno.48107
   PubMed Web of Science ®Google Scholar
• Khreish F, Ebert N, Ries M, et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47(3):721–728. doi: 10.1007/s00259-019-04612-0
   PubMed Web of Science ®Google Scholar
• Rosar F, Hau F, Bartholomä M, et al. Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy. Theranostics. 2021;11(9):4050–4060. doi: 10.7150/thno.56211
   PubMed Web of Science ®Google Scholar
• Ling SW, de Blois E, Hooijman E, et al. Advances in 177Lu-PSMA and 225Ac-PSMA radionuclide therapy for metastatic castration-resistant prostate cancer. Pharmaceutics. 2022;14(10):2166. doi: 10.3390/pharmaceutics14102166
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Schmidt K, Afshar-Oromieh A, et al. Targeted alpha therapy of mCRPC: dosimetry estimate of 213Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;45(1):31–37. doi: 10.1007/s00259-017-3817-y
   PubMed Web of Science ®Google Scholar
• Privé BM, Peters SMB, Muselaers CHJ, et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: A prospective pilot study. Clin Cancer Res. 2021;27(13):3595–3601. doi: 10.1158/1078-0432.CCR-20-4298
   PubMed Web of Science ®Google Scholar
• Satapathy S, Mittal BR, Sood A, et al. 177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. Eur J Nucl Med Mol Imaging. 2022;49(5):1754–1764. doi: 10.1007/s00259-021-05618-3
   PubMed Web of Science ®Google Scholar
• Suman S, Parghane RV, Joshi A, et al. Combined 177 Lu-PSMA-617 PRLT and abiraterone acetate versus 177 Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: an observational study comparing the response and durability. Prostate. 2021;81(15):1225–1234. doi: 10.1002/pros.24219
   PubMed Web of Science ®Google Scholar
• Rosar F, Bader H, Bartholomä M, et al. Addition of standard enzalutamide medication shows synergistic effects on response to [177Lu]Lu-PSMA-617 radioligand therapy in mCRPC Patients with imminent treatment failure—preliminary evidence of pilot experience. Cancers (Basel). 2022;14(11):2691. doi: 10.3390/cancers14112691
   PubMed Web of Science ®Google Scholar
• Violet J, Sandhu S, Iravani A, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61(6):857–865. doi: 10.2967/jnumed.119.236414
   PubMed Web of Science ®Google Scholar